Mark T. Heise

14.2k citations

145 papers · 8.8k indexed · 3 hit papers · h-index 49

Impact in

Infectious Diseases top 0.1%
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Vectors
- COVID-19 Clinical Research Studies
- Viral Infections and Outbreaks Research
- Viral gastroenteritis research and epidemiology
Immunology top 1%
- interferon and immune responses

Papers in

Infectious Diseases 96
- Viral Infections and Vectors 51
- SARS-CoV-2 and COVID-19 Research 36
- Viral Infections and Outbreaks Research 19
- COVID-19 Clinical Research Studies 11
Immunology 45
- interferon and immune responses 23

Co-authors: Ralph S. Baric Thomas E. Morrison Alan C. Whitmore Suresh Mahalingam Matthew B. Frieman Boyd L. Yount Timothy P. Sheahan Lisa E. Gralinski
Journals: Journal of Virology (30 papers)PLoS Pathogens (9 papers)mBio (8 papers)Virology (6 papers)Journal of Medicinal Chemistry (5 papers)
Partner nations: United States Canada Australia

In The Last Decade

Mark T. Heise

138 papers receiving 8.7k citations

Hit Papers

align trajectories log scale

β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells 2021 · 203 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 The Journal of Infectious Diseases
2018 mBio
2011 The Lancet

Peers

Countries citing papers authored by Mark T. Heise

Since Specialization

Citations

This map shows the geographic impact of Mark T. Heise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark T. Heise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark T. Heise more than expected).

Fields of papers citing papers by Mark T. Heise

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark T. Heise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark T. Heise. The network helps show where Mark T. Heise may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark T. Heise, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark T. Heise Line = papers co-authored together Mark T. Heise links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	N -Alkyl Sulfamates as a New Class of nsP2 Cysteine Protease Inhibitors with Broad-Spectrum Antialphaviral Activity Journal of Medicinal Chemistry ·Susan E. Lenk, マサヒコタカハシ, Mohammad Anwar Hossain, Edwin G. Tse, Josh. C. Yelverton, 戴继诚, А.Б. Омирзак, Helen Patrícia Alves Silva, D Buck-Gramcko Groupe D'etude De, 久子金川, Daniel N. Streblow, Rafael M. Couñago, Chuan-Yan Zhu, Mark T. Heise, Timothy M. Willson	2025	0
2	More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5- a ]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication Journal of Medicinal Chemistry ·Han Wee Ong, Grace Williams, Jeffery L. Smith, Arenas Quimbayo, Jason W. Brown, Tammy M. Havener, Sharon Taft-Benz, S. Marmey, Michael A. Newsom, Abu-Seba, Rafael M. Couñago, Christophe Duhaut, Andreas Krämer, Nathaniel J. Moorman, Mark T. Heise, Alison D. Axtman, David H. Drewry, Timothy M. Willson	2024	6
3	Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2 Molecules ·Han Wee Ong, Grace Williams, Jeffery L. Smith, Sharon Taft-Benz, S. Marmey, Arenas Quimbayo, Tammy M. Havener, Michael A. Newsom, Jason W. Brown, Rafael M. Couñago, Christophe Duhaut, Andreas Krämer, Nathaniel J. Moorman, Mark T. Heise, Alison D. Axtman, David H. Drewry, Timothy M. Willson	2024	1
4	Chikungunya Virus RNA Secondary Structures Impact Defective Viral Genome Production Microorganisms ·Laura Levi, Emily A. Madden, Jérémy Boussier, Diana Erazo, Wes Sanders, Thomas Vallet, Claudia Lysia Oliveira Araujo, Nathaniel J. Moorman, Mark T. Heise, Irene J. Ligon	2024	1
5	Host Genetic Variation Impacts SARS-CoV-2 Vaccination Response in the Diversity Outbred Mouse Population Vaccines ·Juan Aguilar Cervera, Elizabeth J. Anderson, Meifika Fatin 'Adilah, Henrik Karge, Sanjay Sarkar, Sharon Taft-Benz, Timothy A. Bell, Ar Geremia, Ch. Cheng, Kenneth H. Dinnon, Pablo Hock, Sarah R. Leist, Emily A. Madden, Ginger D. Shaw, Ande West, Ralph S. Baric, Victoria K. Baxter, Fernando Pardo‐Manuel de Villena, Mark T. Heise, Martin T. Ferris	2024	2
6	Neuroinvasive Flavivirus Pathogenesis Is Restricted by Host Genetic Factors in Collaborative Cross Mice, Independently of Oas1b Journal of Virology ·真幸岩本, Melissa D. Mattocks, Hugo Pestre, Martin T. Ferris, Mark T. Heise, Helen M. Lazear	2023	7
7	Human ACE2 expression, a major tropism determinant for SARS-CoV-2, is regulated by upstream and intragenic elements PLoS Pathogens ·John N. Snouwaert, Leigh A. Jania, Trang Thi Huyen Nguyen, David R. Martinez, Alexandra Schäfer, Nicholas Catanzaro, Kendra L. Gully, Ralph S. Baric, Mark T. Heise, Martin T. Ferris, Elizabeth J. Anderson, Wang Danshi, 大悟三根, Sharon Taft-Benz, Victoria K. Baxter, Jenny P.‐Y. Ting, Beverly H. Koller	2023	9
8	Effect of Viral Strain and Host Age on Clinical Disease and Viral Replication in Immunocompetent Mouse Models of Chikungunya Encephalomyelitis Viruses ·Elizabeth J. Anderson, Gil-Su Choi, Mark T. Heise, Victoria K. Baxter	2023	9
9	Nanoformulated Remdesivir with Extremely Low Content of Poly(2‐oxazoline)‐Based Stabilizer for Aerosol Treatment of COVID‐19 Macromolecular Bioscience ·Jacob D. Ramsey, Ian E. Stewart, Emily A. Madden, Chaemin Lim, Duhyeong Hwang, Mark T. Heise, Anthony J. Hickey, Alexander V. Kabanov	2022	13
10	Forward genetic screen of homeostatic antibody levels in the Collaborative Cross identifies MBD1 as a novel regulator of B cell homeostasis PLoS Genetics ·Meifika Fatin 'Adilah, Kenneth S. Plante, Alan C. Whitmore, Colton L. Linnertz, Emily A. Madden, Hugo Pestre, Jin-suk Kim, Henrik Karge, James G. Xenakis, Timothy A. Bell, Pablo Hock, Ginger D. Shaw, Fernando Pardo‐Manuel de Villena, Martin T. Ferris, Mark T. Heise	2022	3
11	An epithelial-immune circuit amplifies inflammasome and IL-6 responses to SARS-CoV-2 Cell Host & Microbe ·Katherine C. Barnett, Yuying Xie, Takanori Asakura, Dingka Song, Kaixin Liang, Sharon Taft-Benz, Haitao Guo, Shuangshuang Yang, Kenichi Okuda, Rodney C. Gilmore, Anna Irada La Ode Malim, Thomas H. Oguin, Gregory D. Sempowski, Scott H. Randell, Mark T. Heise, Yu L. Lei, Richard C. Boucher, Jenny P.‐Y. Ting	2022	40
12	β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells The Journal of Infectious Diseases ·Shuntai Zhou, Collin S Hill, Sanjay Sarkar, Longping V. Tse, Martin L. Bell, Raymond F. Schinazi, Timothy P. Sheahan, Ralph S. Baric, Mark T. Heise, Ronald Swanstrom Hit paper breakdown →	2021	203
13	Novel modulators of p53-signaling encoded by unknown genes of emerging viruses PLoS Pathogens ·Dina Alzhanova, Kathleen Corcoran, Aubrey Bailey, Kristin M. Long, Sharon Taft-Benz, Rachel L. Graham, Jakub Dolinský, Mark T. Heise, Gabriele Neumann, Peter Halfmann, Yoshihiro Kawaoka, Ralph S. Baric, Blossom Damania, Dirk P. Dittmer	2021	10
14	Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice PLoS Pathogens ·Jessica B. Graham, Regina Antonino de la Cámara, Sarah R. Leist, Alexandra Schäfer, Vineet D. Menachery, Lisa E. Gralinski, Sophia Jeng, Darla R. Miller, Michael A. Mooney, Shannon K. McWeeney, Martin T. Ferris, Fernando Pardo-Manuel de Villena, Mark T. Heise, Ralph S. Baric, Jennifer M. Lund	2021	18
15	Genetic control of alphavirus pathogenesis Mammalian Genome ·Victoria K. Baxter, Mark T. Heise	2018	16
16	Bayesian Diallel Analysis Reveals Mx1 -Dependent and Mx1 -Independent Effects on Response to Influenza A Virus in Mice G3 Genes Genomes Genetics ·Paul L. Maurizio, Martin T. Ferris, Gregory R. Keele, Darla R. Miller, Ginger D. Shaw, Alan C. Whitmore, Ande West, Clayton R. Morrison, Hugo Pestre, Kenneth S. Plante, Adam S. Cockrell, David W. Threadgill, Fernando Pardo‐Manuel de Villena, Ralph S. Baric, Mark T. Heise, William Valdar	2017	15
17	Glycosylation of Mouse DPP4 Plays a Role in Inhibiting Middle East Respiratory Syndrome Coronavirus Infection Journal of Virology ·Kayla M. Peck, Adam S. Cockrell, Boyd L. Yount, Trevor Scobey, Ralph S. Baric, Mark T. Heise	2015	53
18	A Gnotobiotic Mouse Model Demonstrates That Dietary Fiber Protects against Colorectal Tumorigenesis in a Microbiota- and Butyrate-Dependent Manner Cancer Discovery ·Dallas R. Donohoe, Darcy Holley, Leonard B. Collins, Stephanie A. Montgomery, Alan C. Whitmore, Andrew Hillhouse, Kaitlin P. Curry, Sarah W. Renner, Alicia Greenwalt, Elizabeth P. Ryan, Virginia Godfrey, Mark T. Heise, David W. Threadgill, Anna Han, James A. Swenberg, Scott J. Bultman	2014	359
19	An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus Epidemiology and Infection ·Mark T. Heise, Alan C. Whitmore, Jeff Thompson, Subha Kannan, Antoinette A. Grobbelaar, Alan C. Kemp, Janusz T. Pawęska, I.S. Zubkov, Laura White, Robert Swanepoel, Felicity J. Burt	2009	43
20	A Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice PLoS Pathogens ·Anjeanette Roberts, Damon Deming, Christopher D. Paddock, Aaron Cheng, Boyd L. Yount, Leatrice Vogel, Brian D. Herman, Tim Sheahan, Mark T. Heise, Gillian L. Genrich, Sherif R. Zaki, Ralph S. Baric, Kanta Subbarao	2007	335

About Mark T. Heise

Mark T. Heise is a scholar working on Infectious Diseases, Immunology, Public Health, Environmental and Occupational Health, Animal Science and Zoology and Virology, having authored 145 papers that have together received 8.8k indexed citations. Recurring topics across this work include Mosquito-borne diseases and control (58 papers), Viral Infections and Vectors (51 papers), SARS-CoV-2 and COVID-19 Research (36 papers), interferon and immune responses (23 papers), Viral Infections and Outbreaks Research (19 papers), Animal Virus Infections Studies (14 papers), Influenza Virus Research Studies (12 papers) and COVID-19 Clinical Research Studies (11 papers). The work is most often cited by research in Infectious Diseases (5.6k citations), Immunology (2.4k citations), Public Health, Environmental and Occupational Health (2.5k citations), Animal Science and Zoology (811 citations) and Virology (302 citations). Mark T. Heise has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Ralph S. Baric, Thomas E. Morrison, Alan C. Whitmore, Suresh Mahalingam, Matthew B. Frieman, Boyd L. Yount, Timothy P. Sheahan, Lisa E. Gralinski, Herbert W. Virgin and Nestor E. Rulli. Their work appears in journals such as Journal of Virology, PLoS Pathogens, mBio, Virology and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact